2020年　業績集

  1. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial.
    Mateos MV, Nahi H, Legiec W, Grosicki S, Vorobyev V, Spicka I, Hungria V, Korenkova S, Bahlis N, Flogegard M, Bladé J, Moreau P, Kaiser M, Iida S, Laubach J, Magen H, Cavo M, Hulin C, White D, De Stefano V, Clemens PL, Masterson T, Lantz K, O’Rourke L, Heuck C, Qin X, Parasrampuria DA, Yuan Z, Xu S, Qi M, Usmani SZ.
    Lancet Haematol. 2020 May;7(5):e370-e380. doi: 10.1016/S2352-3026(20)30070-3. Epub 2020 Mar 23.
    PMID: 32213342 Clinical Trial.
  2. Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial.
    Dimopoulos MA, Špička I, Quach H, Oriol A, Hájek R, Garg M, Beksac M, Bringhen S, Katodritou E, Chng WJ, Leleu X, Iida S, Mateos MV, Morgan G, Vorog A, Labotka R, Wang B, Palumbo A, Lonial S; TOURMALINE-MM4 study group.
    J Clin Oncol. 2020 Dec 1;38(34):4030-4041. doi: 10.1200/JCO.20.02060. Epub 2020 Oct 6.
    PMID: 33021870 Clinical Trial.
  3. Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies.
    Mateos MV, Spencer A, Nooka AK, Pour L, Weisel K, Cavo M, Laubach JP, Cook G, Iida S, Benboubker L, Usmani SZ, Yoon SS, Bahlis NJ, Chiu C, Ukropec J, Schecter JM, Qin X, O’Rourke L, Dimopoulos MA.
    Haematologica. 2020 Jan 31;105(2):468-477. doi: 10.3324/haematol.2019.217448. Print 2020.
    PMID: 31221782 Free PMC article. Clinical Trial.
  4. Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX.
    Kaufman JL, Dimopoulos MA, White D, Benboubker L, Cook G, Leiba M, Morton J, Joy Ho P, Kim K, Takezako N, Moreau P, Sutherland HJ, Magen H, Iida S, Kim JS, Miles Prince H, Cochrane T, Oriol A, Bahlis NJ, Chari A, O’Rourke L, Trivedi S, Casneuf T, Krevvata M, Ukropec J, Kobos R, Avet-Loiseau H, Usmani SZ, San-Miguel J.
    Blood Cancer J. 2020 Nov 3;10(11):111. doi: 10.1038/s41408-020-00375-2.
    PMID: 33149130 Free PMC article. Clinical Trial.
  5. A multicenter, open-label, phase II study of tirabrutinib (ONO/GS-4059) in patients with Waldenström’s macroglobulinemia.
    Sekiguchi N, Rai S, Munakata W, Suzuki K, Handa H, Shibayama H, Endo T, Terui Y, Iwaki N, Fukuhara N, Tatetsu H, Iida S, Ishikawa T, Shiibashi R, Izutsu K.
    Cancer Sci. 2020 Sep;111(9):3327-3337. doi: 10.1111/cas.14561. Epub 2020 Jul 20.
    PMID: 32639651 Free PMC article. Clinical Trial.
  6. Isatuximab monotherapy in relapsed/refractory multiple myeloma: A Japanese, multicenter, phase 1/2, safety and efficacy study.
    Sunami K, Suzuki K, Ri M, Matsumoto M, Shimazaki C, Asaoku H, Shibayama H, Ishizawa K, Takamatsu H, Ikeda T, Maruyama D, Kaneko H, Uchiyama M, Kiguchi T, Iyama S, Murakami H, Takahashi K, Tada K, Macé S, Guillemin-Paveau H, Iida S.
    Cancer Sci. 2020 Dec;111(12):4526-4539. doi: 10.1111/cas.14657. Epub 2020 Oct 15.
    PMID: 32975869 Free PMC article. Clinical Trial.
  7. Factors associated with suicidal ideation in patients with multiple myeloma.
    Akechi T, Okuyama T, Uchida M, Kubota Y, Hasegawa T, Suzuki N, Komatsu H, Kusumoto S, Iida S.
    Jpn J Clin Oncol. 2020 Dec 16;50(12):1475-1478. doi: 10.1093/jjco/hyaa143.
    PMID: 32779718
  8. Clinical significance of tryptophan catabolism in follicular lymphoma.
    Masaki A, Ishida T, Maeda Y, Ito A, Suzuki S, Narita T, Kinoshita S, Yoshida T, Ri M, Kusumoto S, Komatsu H, Inagaki H, Ueda R, Choi I, Suehiro Y, Iida S.
    Hematol Oncol. 2020 Dec;38(5):742-753. doi: 10.1002/hon.2804. Epub 2020 Sep 29.
    PMID: 32940915
  9. Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma.
    Dimopoulos MA, Jakubowiak AJ, McCarthy PL, Orlowski RZ, Attal M, Bladé J, Goldschmidt H, Weisel KC, Ramasamy K, Zweegman S, Spencer A, Huang JSY, Lu J, Sunami K, Iida S, Chng WJ, Holstein SA, Rocci A, Skacel T, Labotka R, Palumbo A, Anderson KC.
    Blood Cancer J. 2020 Feb 13;10(2):17. doi: 10.1038/s41408-020-0273-x.
    PMID: 32054831 Free PMC article. Review.
  10. Feed-forward regulatory loop driven by IRF4 and NF-κB in adult T-cell leukemia/lymphoma.
    Wong RWJ, Tan TK, Amanda S, Ngoc PCT, Leong WZ, Tan SH, Asamitsu K, Hibi Y, Ueda R, Okamoto T, Ishida T, Iida S, Sanda T.
    Blood. 2020 Mar 19;135(12):934-947. doi: 10.1182/blood.2019002639.
    PMID: 31972002
  11. Autocrine HGF/c-Met signaling pathway confers aggressiveness in lymph node adult T-cell leukemia/lymphoma.
    Totani H, Shinjo K, Suzuki M, Katsushima K, Mase S, Masaki A, Ito A, Ri M, Kusumoto S, Komatsu H, Ishida T, Inagaki H, Iida S, Kondo Y.
    Oncogene. 2020 Aug;39(35):5782-5794. doi: 10.1038/s41388-020-01393-x. Epub 2020 Aug 4.
    PMID: 32747750
  12. Genomic analysis of multiple myeloma using targeted capture sequencing in the Japanese cohort.
    Kanamori T, Sanada M, Ri M, Ueno H, Nishijima D, Yasuda T, Tachita T, Narita T, Kusumoto S, Inagaki A, Ishihara R, Murakami Y, Kobayashi N, Shiozawa Y, Yoshida K, Nakagawa MM, Nannya Y, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Horibe K, Handa H, Ogawa S, Iida S.
    Br J Haematol. 2020 Dec;191(5):755-763. doi: 10.1111/bjh.16720. Epub 2020 May 9.
    PMID: 32386081 Clinical Trial.
  13. Robust CD8+ T-cell proliferation and diversification after mogamulizumab in patients with adult T-cell leukemia-lymphoma.
    Saito M, Ishii T, Urakawa I, Matsumoto A, Masaki A, Ito A, Kusumoto S, Suzuki S, Takahashi T, Morita A, Inagaki H, Iida S, Ishida T.
    Blood Adv. 2020 May 26;4(10):2180-2191. doi: 10.1182/bloodadvances.2020001641.
    PMID: 32433748 Free PMC article.
  14. Clinical utility of target capture-based panel sequencing in hematological malignancies: A multicenter feasibility study.
    Yasuda T, Sanada M, Nishijima D, Kanamori T, Iijima Y, Hattori H, Saito A, Miyoshi H, Ishikawa Y, Asou N, Usuki K, Hirabayashi S, Kato M, Ri M, Handa H, Ishida T, Shibayama H, Abe M, Iriyama C, Karube K, Nishikori M, Ohshima K, Kataoka K, Yoshida K, Shiraishi Y, Goto H, Adachi S, Kobayashi R, Kiyoi H, Miyazaki Y, Ogawa S, Kurahashi H, Yokoyama H, Manabe A, Iida S, Tomita A, Horibe K.
    Cancer Sci. 2020 Sep;111(9):3367-3378. doi: 10.1111/cas.14552. Epub 2020 Jul 17.
    PMID: 32619037 Free PMC article.
  15. Expression, mutation, and methylation of cereblon-pathway genes at pre- and post-lenalidomide treatment in multiple myeloma.
    Tachita T, Kinoshita S, Ri M, Aoki S, Asano A, Kanamori T, Yoshida T, Totani H, Ito A, Kusumoto S, Komatsu H, Yamagata K, Kubo K, Tohkin M, Fukuda S, Iida S.
    Cancer Sci. 2020 Apr;111(4):1333-1343. doi: 10.1111/cas.14352. Epub 2020 Mar 12.
    PMID: 32061138 Free PMC article.
  16. Pembrolizumab plus lenalidomide and dexamethasone in treatment-naive multiple myeloma (KEYNOTE-185): subgroup analysis in Japanese patients.
    Takezako N, Kosugi H, Matsumoto M, Iida S, Ishikawa T, Kondo Y, Ando K, Miki H, Matsumura I, Sunami K, Teshima T, Iwasaki H, Onishi Y, Kizaki M, Izutsu K, Maruyama D, Tobinai K, Ghori R, Farooqui M, Liao J, Marinello P, Matsuda K, Koh Y, Shimamoto T, Suzuki K.
    Int J Hematol. 2020 Nov;112(5):640-649. doi: 10.1007/s12185-020-02953-3. Epub 2020 Sep 19.
    PMID: 32949374
  17. Final results of a phase I study of carfilzomib, lenalidomide, and dexamethasone for heavily pretreated multiple myeloma.
    Sugiura I, Suzuki K, Ri M, Chou T, Takezako N, Sunami K, Ishida T, Izumi T, Ozaki S, Shumiya Y, Iida S.
    Int J Hematol. 2020 Jan;111(1):57-64. doi: 10.1007/s12185-019-02754-3. Epub 2019 Oct 29.
    PMID: 31664647 Clinical Trial.
  18. Daratumumab, lenalidomide, and dexamethasone in Japanese patients with transplant-ineligible newly diagnosed multiple myeloma: a phase 1b study.
    Takamatsu H, Iida S, Shibayama H, Shibayama K, Yamazaki H, Suzuki K.
    Int J Hematol. 2020 May;111(5):692-701. doi: 10.1007/s12185-020-02825-w. Epub 2020 Jan 30.
    PMID: 32002821 Clinical Trial.
  19. Bortezomib administration is a risk factor associated with the development of tumor lysis syndrome in male patients with multiple myeloma: a retrospective study.
    Kondo M, Hotta Y, Yamauchi K, Sanagawa A, Komatsu H, Iida S, Kimura K.
    BMC Cancer. 2020 Nov 17;20(1):1117. doi: 10.1186/s12885-020-07592-9.
    PMID: 33203424 Free PMC article.
  20. Hepatitis B virus reactivation in a myeloma patient with resolved infection who received daratumumab-containing salvage chemotherapy.
    Kikuchi T, Kusumoto S, Tanaka Y, Oshima Y, Fujinami H, Suzuki T, Totani H, Kinoshita S, Asao Y, Narita T, Ito A, Ri M, Komatsu H, Iida S.
    J Clin Exp Hematop. 2020 Jun 20;60(2):51-54. doi: 10.3960/jslrt.19034. Epub 2020 May 13.
    PMID: 32404569 Free PMC article.
  21. Mogamulizumab for adult T-cell leukemia-lymphoma: a multicenter prospective observational study.
    Yonekura K, Kusumoto S, Choi I, Nakano N, Ito A, Suehiro Y, Imaizumi Y, Yoshimitsu M, Nosaka K, Ohtsuka E, Hidaka M, Jo T, Sasaki H, Moriuchi Y, Ogata M, Tatetsu H, Ishitsuka K, Miyazaki Y, Ueda R, Utsunomiya A, Ishida T.
    Blood Adv. 2020 Oct 27;4(20):5133-5145. doi: 10.1182/bloodadvances.2020003053.
    PMID: 33091125 Free PMC article.
  22. R-CHOP-14 versus R-CHOP-14/CHASER for upfront autologous transplantation in diffuse large B-cell lymphoma: JCOG0908 study.
    Kagami Y, Yamamoto K, Shibata T, Tobinai K, Imaizumi Y, Uchida T, Shimada K, Minauchi K, Fukuhara N, Kobayashi H, Yamauchi N, Tsujimura H, Hangaishi A, Tominaga R, Suehiro Y, Yoshida S, Inoue Y, Suzuki S, Tokuhira M, Kusumoto S, Kuroda J, Yakushijin Y, Takamatsu Y, Kubota Y, Nosaka K, Morishima S, Nakamura S, Ogura M, Maruyama D, Hotta T, Morishima Y, Tsukasaki K, Nagai H.
    Cancer Sci. 2020 Oct;111(10):3770-3779. doi: 10.1111/cas.14604. Epub 2020 Sep 11.
    PMID: 32767806 Free PMC article. Clinical Trial.
  23. Ultra-high sensitivity HBsAg assay can diagnose HBV reactivation following rituximab-based therapy in patients with lymphoma.
    Kusumoto S, Tanaka Y, Suzuki R, Watanabe T, Nakata M, Sakai R, Fukushima N, Fukushima T, Moriuchi Y, Itoh K, Nosaka K, Choi I, Sawa M, Okamoto R, Tsujimura H, Uchida T, Suzuki S, Okamoto M, Takahashi T, Sugiura I, Onishi Y, Kohri M, Yoshida S, Kojima M, Takahashi H, Tomita A, Atsuta Y, Maruyama D, Tanaka E, Suzuki T, Kinoshita T, Ogura M, Ueda R, Mizokami M.
    J Hepatol. 2020 Aug;73(2):285-293. doi: 10.1016/j.jhep.2020.03.009. Epub 2020 Mar 17.
    PMID: 32194183
  24. A prospective trial of vaccine to prevent hepatitis B virus reactivation after hematopoietic stem cell transplantation.
    Nishikawa K, Kimura K, Kanda Y, Sugiyama M, Kakihana K, Doki N, Ohashi K, Bae SK, Takahashi K, Ishihara Y, Mizuno I, Onishi Y, Onozawa M, Onizuka M, Yamamoto M, Ishikawa T, Inoue K, Kusumoto S, Hashino S, Saito H, Kanto T, Sakamaki H, Mizokami M.
    Bone Marrow Transplant. 2020 Jul;55(7):1388-1398. doi: 10.1038/s41409-020-0833-5. Epub 2020 Feb 18.
    PMID: 32071416 Free PMC article. Clinical Trial.
  25. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRI MEUR-IVL): a multicentre, single-arm, phase 2 trial.
    Shimada K, Yamaguchi M, Atsuta Y, Matsue K, Sato K, Kusumoto S, Nagai H, Takizawa J, Fukuhara N, Nagafuji K, Miyazaki K, Ohtsuka E, Okamoto M, Sugita Y, Uchida T, Kayukawa S, Wake A, Ennishi D, Kondo Y, Izumi T, Kin Y, Tsukasaki K, Hashimoto D, Yuge M, Yanagisawa A, Kuwatsuka Y, Shimada S, Masaki Y, Niitsu N, Kiyoi H, Suzuki R, Tokunaga T, Nakamura S, Kinoshita T.
    Lancet Oncol. 2020 Apr;21(4):593-602. doi: 10.1016/S1470-2045(20)30059-0. Epub 2020 Mar 11.
    PMID: 32171071 Clinical Trial.
  26. JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-4. Mantle cell lymphoma (MCL).
    Okamoto M, Kusumoto S.
    Int J Hematol. 2020 Jan;111(1):5-15. doi: 10.1007/s12185-019-02784-x. Epub 2019 Dec 10.
    PMID: 31823126 No abstract available.
  27. Tumor lysis syndrome associated with nivolumab plus ipilimumab combination therapy in a melanoma patient.
    Magara A, Kato H, Oda T, Nakamura M, Komatsu H, Morita A.
    J Dermatol. 2020 Nov;47(11):e411-e412. doi: 10.1111/1346-8138.15547. Epub 2020 Aug 27.
    PMID: 32856327 No abstract available.
  28. A survey of blood transfusion errors in Aichi Prefecture in Japan: Identifying major lapses threatening the safety of transfusion recipients.
    Ri M, Kasai M, Kohno A, Kondo M, Sawa M, Kinoshita T, Sugiura I, Miura Y, Yamamoto K, Saito TI, Ozawa Y, Matsushita T, Kato H.
    Transfus Apher Sci. 2020 Jun;59(3):102735. doi: 10.1016/j.transci.2020.102735. Epub 2020 Jan 27.
    PMID: 32019735